<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Implantable ocular lenses</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Alcon sweetens offer for Staar, major shareholders still unimpressed</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Alcon AG reported on Dec. 9 that it had sweetened its offer for intraocular lens maker Staar Surgical Co., raising its offer by roughly 10% to $30.75 a share from its prior bid of $28 a share. The revised offer comes on the heels of the expiration of Staar’s go-shop period on Dec. 8, in which Lake Forest, Calif.-based Staar said no superior offers were received.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726742</guid>
      <pubDate>Wed, 10 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726742-alcon-sweetens-offer-for-staar-major-shareholders-still-unimpressed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Broken-contract.webp?t=1675372768" type="image/png" medium="image" fileSize="230802">
        <media:title type="plain">Pen and ripped contract</media:title>
      </media:content>
    </item>
    <item>
      <title>Alcon reports strong 3Q, unsure about Staar merger</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Alcon AG reported its financial results for the three- and nine-month periods ending Sept. 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant currency basis, as compared to the same quarter of the previous year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725980</guid>
      <pubDate>Thu, 13 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725980-alcon-reports-strong-3q-unsure-about-staar-merger</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businessperson-completing-checklist.webp?t=1738778263" type="image/jpeg" medium="image" fileSize="115231">
        <media:title type="plain">Businessperson completing checklist</media:title>
      </media:content>
    </item>
    <item>
      <title>Staar has no competing bids, another shareholder rejects Alcon buy</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Staar Surgical Co. reported that its 45-day window shop period ended on Sept. 19 with no competing bids made, and it urged its shareholders to vote in favor of completing the $1.5 billion cash merger with Alcon AG.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724211</guid>
      <pubDate>Mon, 22 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724211-staar-has-no-competing-bids-another-shareholder-rejects-alcon-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Purple-pie-chart.webp?t=1706041689" type="image/jpeg" medium="image" fileSize="65416">
        <media:title type="plain">Purple pie chart </media:title>
      </media:content>
    </item>
  </channel>
</rss>
